نتائج البحث - Helena W. Rodbard

تنقيح النتائج
  1. 1
    Management of Type 2 Diabetes – Methods for Addition of Prandial to Basal Insulin

    Management of Type 2 Diabetes – Methods for Addition of Prandial to Basal Insulin حسب Helena, W Rodbard, Karolicki, Boris

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل احصل على النص الكامل
    نص
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes

    Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes حسب Leigh Perreault, Helena W. Rodbard, Virginia Valentine, Eric L. Johnson

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection

    Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection حسب Erin D. Michos, George L. Bakris, Helena W. Rodbard, Katherine R. Tuttle

    منشور في 2023
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes

    The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People... حسب Helena W. Rodbard, Anne L. Peters, April Slee, Anjun Cao, Shana Traina, Maria Alba

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Treatment intensification with an insulin degludec (<scp>IDeg</scp>)/insulin aspart (<scp>IAsp</scp>) co‐formulation twice daily compared with basal <scp>IDeg</scp> and prandial <scp>IAsp</scp> in type 2 diabetes: a randomized, controlled phase <scp>III</scp> trial

    Treatment intensification with an insulin degludec (<scp>IDeg</scp>)/insulin aspart (<scp>IAsp</scp>) co‐formulation twice daily compared with basal <scp>IDeg</scp> and prandial <s... حسب Helena W. Rodbard, Bertrand Cariou, Thomas R. Pieber, Lars Endahl, Jeppe Zacho, John Graham Cooper

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin

    Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin حسب Helena W. Rodbard, Jochen Seufert, Naresh Aggarwal, A. Cao, Albert Fung, Michael Pfeifer, Maria Alba

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: <scp>A</scp> randomized, 18‐week, open‐label, phase 3 trial (onset 3)

    Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: <scp>A</scp> randomized, 18‐week, open‐label, phase 3... حسب Helena W. Rodbard, Devjit Tripathy, Maricela Vidrio Velázquez, Marek Demissie, Søren C. Tamer, Milivoj Piletič

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Safety and efficacy of insulin degludec/liraglutide (<scp>ID</scp>egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the <scp>DUAL IV</scp> trial

    Safety and efficacy of insulin degludec/liraglutide (<scp>ID</scp>egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabete... حسب Helena W. Rodbard, Bruce W. Bode, Stewart B. Harris, Ludger Rose, Lucine Lehmann, Henrik Jarlov, Jerry Thurman

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes

    Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes حسب Bernard Zinman, Athena Philis‐Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W. Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes

    A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes حسب Joseph M. Tibaldi, Martin Hadley‐Brown, Andreas Liebl, Steffen Haldrup, Viktor Sandberg, Michael Lyng Wolden, Helena W. Rodbard

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial

    Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled tr... حسب Andrew Ahmann, Helena W. Rodbard, Julio Rosenstock, Jorma Lahtela, Luis De Loredo, Karen Tornøe, A. Boopalan, Michael A. Nauck

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial

    Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial حسب Helena W. Rodbard, Bertrand Cariou, Bernard Zinman, Yehuda Handelsman, Athena Philis‐Tsimikas, Trine Vang Skjøth, Ashma Rana, Chantal Mathieu

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes

    Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes حسب Julio Rosenstock, Juan P. Frías, Helena W. Rodbard, Santiago Tofé, E. Sears, Ruth Huh, Laura Fernández Landó, Hiren Patel

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial

    One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial... حسب Stephen Gough, Bruce W. Bode, Vincent Woo, Helena W. Rodbard, Sultan Linjawi, M. Zacho, Pamela D. Reiter, John B. Buse

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (<scp>BEGIN</scp>: <scp>VICTOZA ADD‐ON</scp>)

    A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (<scp>BEGIN</scp>: <scp>VICTOZA ADD‐ON</scp>) حسب Chantal Mathieu, Helena W. Rodbard, Bertrand Cariou, Yehuda Handelsman, Athena Philis‐Tsimikas, Ann Marie Ocampo Francisco, Ashma Rana, Bernard Zinman

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Is adiposopathy (sick fat) an endocrine disease?

    Is adiposopathy (sick fat) an endocrine disease? حسب Harold Bays, J. Michael González-Campoy, Robert R. Henry, Donald A. Bergman, Abbas E. Kitabchi, Alan B. Schorr, Helena W. Rodbard

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial

    Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Tr... حسب Liana K. Billings, Ankur Doshi, D. Gouet, Alejandra Oviedo, Helena W. Rodbard, Nikolaοs Tentolouris, Randi Grøn, Natalie Halladin, Esteban Jódar

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

    Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets حسب J. Hans DeVries, Stephen C. Bain, Helena W. Rodbard, Jochen Seufert, David A. D’Alessio, Anne Bloch Thomsen, Marcin Zychma, Julio Rosenstock

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target

    One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target حسب Julio Rosenstock, Helena W. Rodbard, Stephen C. Bain, David A. D’Alessio, Jochen Seufert, Anne Bloch Thomsen, Claus Bo Svendsen, J. Hans DeVries

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity

    Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity حسب Harold Bays, J. Michael González-Campoy, George A. Bray, Abbas E. Kitabchi, Donald A. Bergman, Alan B. Schorr, Helena W. Rodbard, Robert R. Henry

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: